A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers

Last updated: June 16, 2025
Sponsor: Alnylam Pharmaceuticals
Overall Status: Active - Recruiting

Phase

1

Condition

Obesity

Hypertriglyceridemia

Treatment

Placebo

ALN-4324

Clinical Study ID

NCT06845202
ALN-4324-001
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Has a body mass index (BMI) of ≥27 kg/m^2 and <40 kg/m^2

Exclusion

Exclusion Criteria:

  • Has known human immunodeficiency virus (HIV) infection; or known current or chronichepatitis C virus or hepatitis B virus infection

Note: other protocol defined inclusion/exclusion criteria apply

Study Design

Total Participants: 84
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
March 03, 2025
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • Clinical Trial Site

    Laval, Quebec H7V 4B3
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.